首页> 外文期刊>Obstetrics and Gynecology: Journal of the American College of Obstetricians and Gynecologists >Methotrexate prophylaxis for persistent ectopic pregnancy after conservative treatment by salpingostomy.
【24h】

Methotrexate prophylaxis for persistent ectopic pregnancy after conservative treatment by salpingostomy.

机译:经输卵管造口术保守治疗后甲氨蝶呤预防持续性异位妊娠。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To investigate whether the incidence of persistent ectopic pregnancy after linear salpingostomy can be reduced by prophylactic administration of a single dose of methotrexate postoperatively. METHODS: Women who underwent linear salpingostomy for treatment of unruptured ectopic pregnancy and who agreed to participate in the study (n = 129) were randomly assigned to the prophylaxis or control group. Women with anemia, renal insufficiency, or liver disease were excluded. In the prophylaxis group, patients received a single dose of methotrexate, 1 mg/kg intramuscularly, within 24 hours postoperatively. No treatment was used in the control group. Both groups were followed with serial serum beta-hCG titers; titers were measured on the seventh postoperative day, then every 72 hours until levels were lower than 15 mIU/mL. A blood count and chemistry panel were also obtained on postoperative day 7, and any side effects related to methotrexate were noted. Persistent ectopic pregnancy was defined as a rise in the serum beta-hCG level or a decline of less than 20% between two consecutive measurements taken 3 days apart. RESULTS: A total of 116 women completed the postoperative follow-up: 54 in the prophylaxis group and 62 in the control group. Ten women had persistent ectopic pregnancy, one in the prophylaxis group (1.9%) and nine among the controls (14.5%); this difference was statistically significant (P < .05). The relative risk of developing persistent ectopic pregnancy after prophylactic methotrexate was 0.13 (95% confidence interval 0.02, 0.97). Three women (5.5%) reported mild side effects after methotrexate, but these resolved spontaneously. CONCLUSION: The incidence of persistent ectopic pregnancy was significantly reduced after a single prophylactic dose of systemic methotrexate administered postoperatively. This regimen is safe and can be used to decrease the extent of postoperative monitoring after conservative treatment of unruptured ectopic pregnancy.
机译:目的:探讨线形输卵管造口术术后持续性异位妊娠的发生率是否可以通过术后预防性使用单剂量甲氨蝶呤来降低。方法:接受线性输卵管造口术治疗未破裂性异位妊娠并同意参加研究的妇女(n = 129)被随机分配到预防组或对照组。患有贫血,肾功能不全或肝病的妇女被排除在外。在预防组中,患者在术后24小时内肌内注射单剂量甲氨蝶呤,剂量为1 mg / kg。对照组未使用任何治疗。两组均接受连续的血清β-hCG滴度测定。在术后第七天测量滴度,然后每72小时测量一次,直到水平低于15 mIU / mL。术后第7天也获得了血细胞计数和化学检查结果,并注意到与甲氨蝶呤有关的任何副作用。持续性异位妊娠定义为相隔3天的两次连续测量之间血清β-hCG水平升高或下降小于20%。结果:共有116名妇女完成了术后随访:预防组54例,对照组62例。持续性异位妊娠的女性有10名,预防组1名(1.9%),对照组中9名(14.5%);这种差异具有统计学意义(P <.05)。预防性甲氨蝶呤治疗后发生持续性异位妊娠的相对风险为0.13(95%置信区间0.02、0.97)。三名妇女(5.5%)接受甲氨蝶呤治疗后出现轻度副作用,但这些症状会自发缓解。结论:术后单次预防性给予全身氨甲蝶呤后,持续性异位妊娠的发生率明显降低。这种方案是安全的,可用于保守治疗未破裂的异位妊娠后减少术后监测的程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号